FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030929501> ?p ?o ?g. }

• W3030929501 abstract "e15523 Background: Small studies have shown that therapy with dacarbazine and temozolomide give up to 34% tumoral response rates in endocrine carcinomas. The aim of this large retrospective multicentric study was to evaluate efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-FU in endocrine carcinomas. Methods: Patients were recruited in 6 French and 1 German centers. All patients with well (WDEC) or poorly-differentiated endocrine carcinoma (PDEC), whatever the primary, and who have been treated with dacarbazine or temozolomide associated or not with iv 5-FU or capecitabine, were included. Response rates were evaluated according to RECIST criteria by one of the investigator and toxicity according to National Cancer Institute Common criteria. Results: 86 patients were included : 36 women, median age 61.7 years (27.7 - 85.7), 67 WHO-PS 0–1. Primaries were : pancreas (n=34), digestive tract (n=23), thyroid (n=9), lung (n=6), other (n=6), unknown (n=8). 64 patients had WDEC and 11 PDEC (11 not determined). The number of previous systemic treatments (chemotherapy, chemoembolization, radionuclide therapy) was: 0 (n=16), 1 (n=25), 2 (n=25), 3 (n=14), 4 and more (n=6). Treatments received were : dacarbazine (n=3), temozolomide (n=19), dacarbazine + 5-FU (n=48), temozolomide + capecitabine (n=16). Evaluation was impossible in two patients. Tumoral response rates (partial and stabilization) were 61.2% in WDEC and 18.2% in PDEC. The best response rates in WDEC were : partial response (n=6; 9.7%), stabilization (n=32; 51.6%), progression (n=24; 38.7%) without significant differences between regimens and primary location. Response rates in WDEC were 88.9%, 71.4% and 64.7% in first, second and third line therapies, respectively. Median progression free survival in WDEC was 5.7 months (0.1–41.7). Grade 3–4 toxicities were hematologic (n=8), digestive (n=10), infection (n=3). Conclusions: Dacarbazine and temozolomide therapy showed high partial response and stabilization rates up to 3rd line therapy in well-differentiated endocrine carcinoma, with moderate toxicity. MGMT tumoral status is currently investigated. No significant financial relationships to disclose." @default.
• W3030929501 created "2020-06-05" @default.
• W3030929501 creator A5001546426 @default.
• W3030929501 creator A5011309373 @default.
• W3030929501 creator A5011453849 @default.
• W3030929501 creator A5021016040 @default.
• W3030929501 creator A5035203042 @default.
• W3030929501 creator A5048971171 @default.
• W3030929501 creator A5064369229 @default.
• W3030929501 creator A5067116958 @default.
• W3030929501 creator A5076309223 @default.
• W3030929501 creator A5082552782 @default.
• W3030929501 date "2009-05-20" @default.
• W3030929501 modified "2023-10-16" @default.
• W3030929501 title "Efficacy and tolerance of chemotherapy with dacarbazine or temozolomide associated or not with 5-fluorouracil (5-FU) in endocrine carcinomas: A retrospective multicentric study from the Groupe des Tumeurs Endocrines (GTE)" @default.
• W3030929501 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e15523" @default.
• W3030929501 hasPublicationYear "2009" @default.
• W3030929501 type Work @default.
• W3030929501 sameAs 3030929501 @default.
• W3030929501 citedByCount "0" @default.
• W3030929501 crossrefType "journal-article" @default.
• W3030929501 hasAuthorship W3030929501A5001546426 @default.
• W3030929501 hasAuthorship W3030929501A5011309373 @default.
• W3030929501 hasAuthorship W3030929501A5011453849 @default.
• W3030929501 hasAuthorship W3030929501A5021016040 @default.
• W3030929501 hasAuthorship W3030929501A5035203042 @default.
• W3030929501 hasAuthorship W3030929501A5048971171 @default.
• W3030929501 hasAuthorship W3030929501A5064369229 @default.
• W3030929501 hasAuthorship W3030929501A5067116958 @default.
• W3030929501 hasAuthorship W3030929501A5076309223 @default.
• W3030929501 hasAuthorship W3030929501A5082552782 @default.
• W3030929501 hasConcept C121608353 @default.
• W3030929501 hasConcept C126322002 @default.
• W3030929501 hasConcept C143998085 @default.
• W3030929501 hasConcept C2776694085 @default.
• W3030929501 hasConcept C2777389519 @default.
• W3030929501 hasConcept C2777909004 @default.
• W3030929501 hasConcept C2779984678 @default.
• W3030929501 hasConcept C2780456651 @default.
• W3030929501 hasConcept C2780964509 @default.
• W3030929501 hasConcept C31760486 @default.
• W3030929501 hasConcept C526805850 @default.
• W3030929501 hasConcept C71924100 @default.
• W3030929501 hasConcept C90924648 @default.
• W3030929501 hasConceptScore W3030929501C121608353 @default.
• W3030929501 hasConceptScore W3030929501C126322002 @default.
• W3030929501 hasConceptScore W3030929501C143998085 @default.
• W3030929501 hasConceptScore W3030929501C2776694085 @default.
• W3030929501 hasConceptScore W3030929501C2777389519 @default.
• W3030929501 hasConceptScore W3030929501C2777909004 @default.
• W3030929501 hasConceptScore W3030929501C2779984678 @default.
• W3030929501 hasConceptScore W3030929501C2780456651 @default.
• W3030929501 hasConceptScore W3030929501C2780964509 @default.
• W3030929501 hasConceptScore W3030929501C31760486 @default.
• W3030929501 hasConceptScore W3030929501C526805850 @default.
• W3030929501 hasConceptScore W3030929501C71924100 @default.
• W3030929501 hasConceptScore W3030929501C90924648 @default.
• W3030929501 hasLocation W30309295011 @default.
• W3030929501 hasOpenAccess W3030929501 @default.
• W3030929501 hasPrimaryLocation W30309295011 @default.
• W3030929501 hasRelatedWork W2011916383 @default.
• W3030929501 hasRelatedWork W2073885660 @default.
• W3030929501 hasRelatedWork W2247624284 @default.
• W3030929501 hasRelatedWork W2280667057 @default.
• W3030929501 hasRelatedWork W2324032012 @default.
• W3030929501 hasRelatedWork W2512663019 @default.
• W3030929501 hasRelatedWork W3158956181 @default.
• W3030929501 hasRelatedWork W4235705773 @default.
• W3030929501 hasRelatedWork W4240082975 @default.
• W3030929501 hasRelatedWork W4306822619 @default.
• W3030929501 isParatext "false" @default.
• W3030929501 isRetracted "false" @default.
• W3030929501 magId "3030929501" @default.
• W3030929501 workType "article" @default.